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Background: Advancing female age remains a difficult problem in infertility treatment. Ovarian angiogenesis plays
an important role in follicular development and the activation of ovarian angiogenesis has been emerged as a new
strategy for the improvement of age-related decline of oocyte quality. BMP-6 affect gonadotropin signals in
granulosa cells and it promotes normal fertility by enabling appropriate response to LH and normal oocyte quality.
BMP-6 has a potential role in regulation of angiogenesis and regulates the expression of inhibitor of DNA-binding
proteins (Ids). Ids involved in the control and timing of follicle selection and granulosa cells differentiation.
Especially, Id-1 is well-characterized target of BMP-6 signaling. Therefore, this study investigated whether
co-administration of BMP-6 during superovulation process improves ovarian response, oocyte quality and
expression of Id-1 and vascular endothelial growth factor (VEGF) in the ovary of aged female using a mouse model.
Methods: Aged C57BL/6 female mice (26–31 weeks old) were superovulated by injection with 0.1 mL of 5 IU
equine chorionic gonadotropin (eCG) containing recombinant mouse BMP-6 at various doses (0, 0.01, 0.1, 1, and
10 ng), followed by injection with 5 IU human chorionic gonadotropin (hCG) 48 h later. Then, the mice were
immediately paired with an individual male. The aged control group was superovulated without BMP-6. Young
mice of 6–9 weeks old were superovulated without BMP-6 as a positive control for superovulation and in vitro
culture of embryos. Eighteen hours after hCG injection, zygotes were retrieved and cultured for 4 days. Both ovaries
of each mouse were provided in the examination of ovarian expression of Id-1 and VEGF by reverse
transcriptase-polymerase chain reaction, western blot, and immunohistochemistry.
Results: Administration of 0.1 ng BMP-6 significantly increased the number and blastocyst formation rate of
oocytes ovulated and ovarian expression of Id-1 and VEGF compared to aged control mice. These increased levels
were comparable to those of young control mice.
Conclusions: This result suggests that BMP-6 during ovulation induction plays an important role in improvement of
oocyte quality and ovarian response of aged female, possibly by regulating of ovarian Id-1 and VEGF expression.
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Despite advancing female age becomes an important
factor for increasing incidence of infertility, it remains a
difficult problem in infertility treatment. A major cause
for age-related decline of fertility is the deterioration of
oocyte quality and ovarian response [1,2]. However,
there is no clinically effective method to improve the
oocyte quality in old women.
Ovarian angiogenesis plays an important role in follicular
growth and the selection of dominant follicle by allowing
the delivery of adequate nutrition, hormonal supply and
oxygen from stromal blood vessels to induce oocytes with
high quality [3-6]. Tatone et al. [7] suggested a possible
mechanism that age-related nuclear and cytoplasmic
damage may occur as a result of inadequate ovarian
angiogenesis in primordial follicles as well as in ovarian
stroma vessels. These results suggest that the activation
of ovarian angiogenesis could be a new strategy for the
improvement of age-related decline of oocyte quality.
Bone morphogenetic proteins (BMPs) are members of
the transforming growth factor β (TGF-β) superfamily
which plays a critical role in the development of
mammalian ovarian follicles [8,9]. Mutations in the
Bmp genes or their receptors result in impaired female
fertility such as decreased granulosa cell proliferation,
abnormal oocyte growth, and failure of follicle development
[10-13]. The BMP-6 is highly expressed in mammalian
oocytes as well as other cell types [14,15]. In vitro extensive
studies have showed that BMP-6 seems to affect
gonadotropin signals in granulosa cells of several mam-
malian species, although it offered conflicting results
[16-21]. In vivo study using BMP-6 null mice also
demonstrated that BMP-6 promotes normal fertility by
enabling appropriate response to LH and normal oocyte
quality [22].
Besides this role, BMP-6 has a potential role in
regulation of angiogenesis by affecting endothelial cells
(ECs) differentiation, migration, proliferation, and tube
formation [23,24]. BMP-6 regulates the expression of
inhibitor of DNA-binding proteins (Ids) in the ovine
ovarian follicles [25]. Id proteins are negative transcriptional
regulators, which lack a basic DNA-binding domain and
block subsequent transcriptional activity by forming
heterodimer with helix-loop-helix (bHLH) transcription
factor [26]. It has been speculated that Ids are involved
in the control and timing of follicle selection and granulosa
cells differentiation in avian species [27,28]. Mammalian Id
superfamily consists of four isoforms (Id-1, Id-2, Id-3, and
Id-4) [29]. Especially, Id-1 is a well-characterized target of
BMP-6 signaling [23,24] and plays a role in angiogenesis
through activation of the vascular endothelial growth factor
(VEGF) [30,31].
However, to our knowledge, there have been no studies
on the effects of BMP-6 on ovarian response andangiogenesis, and oocyte quality according to the female
age. This study examined whether BMP-6 administration
during superovulation process affects ovarian response,
oocyte quality and expression of Id-1 and VEGF in the
ovary of aged female using a mouse model.
Methods
This study was approved by the Institutional Review
Board of Pusan National University Hospital, Korea. All
experiments with mice were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health, approved by the Pusan
National University Hospital Institutional Animal Care and
Use Committee.
Animals
C57BL/6 inbred female mice were purchased from
Korea Experimental Animal Center (Daegu, Korea).
The mice were maintained on light(L)-dark(D) cycle
with 14/10 h L/D with food and water available ad libitum.
Administration of BMP-6 during superovulation
Aged female mice of 26–31 weeks old were superovulated
by intraperitoneal injection with 0.1 mL of 5 IU equine
chorionic gonadotropin (eCG) (Sigma, St. Louis, MO,
USA) containing various doses (0, 0.01, 0.1, 1, and 10 ng) of
recombinant mouse BMP-6 (R&D Systems, Minneapolis,
MN, USA), followed by injection of 5 IU of human
chorionic gonadotropin (hCG, Sigma) approximately 48
hours later. Then the mice were immediately paired with
an individual male that previously tested for fertility. The
following morning the mice were inspected, and those with
a confirmed vaginal plug were considered mated and
fertilized. The aged control group was superovulated
without BMP-6. Young mice of 6–9 weeks old were also
superovulated without BMP-6 as a positive control for
ovarian stimulation and in vitro culture of embryos.
Zygotes collection and in vitro culture of embryos
Eighteen hours after hCG injection, female mice with a
confirmed vaginal plug were sacrificed by cervical
dislocation. Cumulus-enclosed one-cell embryos (zygotes)
were retrieved from the oviductal ampulae and denuded
by incubation for 1 minute with 0.1% hyaluronidase
(Sigma) in Dulbecco's phosphate buffered saline (dPBS;
Gibco BRL, Grand Island, NY, USA). Zygotes retrieved
from each were individually pooled and washed three
times in P1 medium (Irvine Scientific, Santa Ana, CA,
USA) with 10% serum substitute supplement (SSS; Irvine
Scientific). All the zygotes except for those with cell
fragmentation were cultured in 30 μl drops of P1 medium
with 10% SSS for the first 2 days, and then blastocyst
medium (Irvine Scientific) with 10% SSS for the later 2
days under paraffin-oil at 37°C in a 5% CO2 humidity
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culture. When the retrieved one cell embryos developed
to 2-cells embryo in the first day of culture, we included
the data in this study. However, unless all retrieved one
cell embryos developed to 2-cell embryo, we excluded the
data of the mouse without developed 2-cell embryos. In
this respect, we defined the retrieved one-cell embryo as
real zygotes.
Ovary collection and examination of ovarian Id-1 and
VEGF expression
Just after the retrieval of the zygotes, both ovaries of each
mouse were collected. For the examination of ovarian
expression of Id-1 and VEGF, each ovary was randomly
allocated to half for reverse transcriptase-polymerase chain
reaction (RT-PCR), half for western blot and a whole for
immunohistochemistry (IHC).
RT-PCR
Total RNA was isolated from frozen tissue using Trizol re-
agent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s recommendation. RNA was eluted in
RNase-free water and stored at −80°C until RT-PCR
analysis. The cDNA was synthesized from 5 μg of total
RNA with AMV Reverse Transcriptase (Promega, Madison,
WI, USA) using a random hexamer (Bioneer, Daejeon,
Korea) at 42°C for 1 hour followed by inactivate the en-
zyme at 95°C for 5 minutes. Template cDNA was sub-
jected to PCR amplification using gene-specific sense and
antisense primers. PCR conditions were denaturation at
95°C for 30 seconds, specific annealing temperature for 30
seconds, and extension at 72°C for 30 seconds in a
thermal cycle. The primers of each gene are as follows:
5’-CTGCTCTACGACATGAACGGCTG -3’ (sense) and
5’-CGACACAAGATGCGATCGTC -3’ (antisense) for Id-1
(32 cycles); 5’-CTTGTTCAGAGC GGAGAAAGC- 3’
(sense) and 5’-ACATCTGCAAGTACGTTCGTT-3’ (anti-
sense) for VEGF (40 cycles); and 5’-ACCACAGTCCAT
GCCATCAC-3’ (sense) and 5’-TCCACCACCCTGTT
GCTGTA-3’ (antisense) for GAPDH (25 cycles). GAPDH
mRNA was quantified in each sample as an internal control
to normalize the level of mRNA among samples. The PCR
products were examined by 2% agarose gel electrophoresis.
Data are representative of at least three independent
experiments. The relative density of PCR bands were
quantified and normalized relative to the control band
with the National Institutes of Health (NIH) Image
program (Image-J 1.35d, NIH, Bethesda, MD, USA).
Western blot analysis
Protein was extracted by homogenization of ovaries in the
presence of ice-cold lysis buffer (50 mM Tris–HCl (pH
7.5), 150 mM NaCl, 1% Nonidet P-40, and 1 mM EDTA)
containing protease inhibitor. The protein content of thecell lysate was determined with Bradford reagent (Bio-Rad,
Hercules, CA, USA) using bovine serum albumin (BSA) as
the standard. Sixty micrograms of protein were separated
by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to a polyvinyli-
dene fluoride (PVDF) membrane (Millipore, Bedford,
MA, USA). The membrane was incubated with anti-Id-1
polyclonal antibody (1:200; Santa Cruz Biotech, Santa
Cruz, CA, USA), anti-VEGF monoclonal antibody (1:100;
R&D Systems) and anti-β-actin monoclonal antibody
(1:5,000; Sigma) in tris-buffered saline (TBS) containing 1%
tween 20 (TBS-T) supplemented with skim milk overnight
at 4°C. After washing three times with TBS-T, the blotted
membranes were incubated with horseradish peroxidase
(HRP)-conjugated goat antibody (Santa Cruz Biotech) for
30 minutes at room temperature. After washing three times
with TBS-T, the proteins bands were visualized using an
enhanced chemiluminescence (ECL) detection system
according to the recommended procedure (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). Actin expression
was used as the control. Data are representative of at least
three independent experiments. The relative density of
protein bands were quantified and normalized relative to
the control band with the National Institutes of Health
(NIH) Image program (Image-J 1.35d).Immunohistochemistry
Immunohistochemistry was performed on 4 μm-thick,
formalin-fixed paraffin sections of ovary tissues using
Zymed's SuperPicTure™ Polymer detection system (Zymed
Laboratories-Invitrogen, San Francisco, CA, USA). Serial
sections of the ovary were mounted on coated slides and
placed in an oven at 60°C for 1 hour. The slides were then
deparaffinized in xylene and dehydrated in a graded series
of ethanol. The slides were boiled in 10 mM citrate buffer
(pH 6.0) for 15 minutes in a microwave oven. The
endogenous peroxidase was quenched with 0.3% hydrogen
peroxide at room temperature for 10 minutes, and then
tissues were rinsed four times for 5 minutes each in PBS.
The sections were incubated overnight at 4°C with the
primary Id-1 antibody (Santa Cruz Biotech) and VEGF
antibody (Lab Vision, Fremont, CA, USA) at 1:100
dilutions. The remaining steps were performed according
to the instructions supplied with the kit. After washing
three times with PBS, the samples were incubated with
biotinylated-conjugated secondary antibody and HRP
coupled to streptavidin-conjugated antibody for 15 minutes
at room temperature and washed three times with PBS.
The sections were stained with 3,3-diaminobenzidine
(DAB), counterstained with Mayer’s hematoxylin (Sigma),
and mounted with histomount solution (Invitrogen). The
results were assessed by two pathologists using a light
microscope.
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An SPSS program (version 12.0) was used for statistical
analysis, and all data were presented as a mean±SD. The
number of zygotes retrieved and blastocyst formation rate
according to treated BMP-6 concentration were analyzed
by one-way analysis of variance with post hoc multiple
comparisons by Bonferroni-Dunn analysis. Statistical
analysis for comparison of expression of Id-1 and VEGF
was performed by one-way ANOVA. A P value of < .05
was considered statistically significant.
Results
To investigate whether BMP-6 effects on ovarian response
and developmental competency of oocytes in aged female
mice, BMP-6 was co-administered to female mice of 26–31
weeks old at different doses (0, 0.01, 0.1, 1, and 10 ng)
during superovulation. The mean number of zygotes
retrieved was 14.7 in 0.1 ng BMP-6 concentration, which
was significantly increased compared to 11.6 in the aged
control mice (P < 0.05), and this increased number was
comparable to 15.1 in the young mice used as a positive
control. Especially, 10 ng BMP-6 greatly reduced the
number of zygotes retrieved. On the contrary, the mean
percentage of fragmented zygotes among those retrieved
was 5.3% in 0.1 ng BMP-6, which was significantly lower
than those of aged control mice, 0.01 ng and 10 ng BMP-6
concentrations. The development rates to blastocyst stage
were also significantly increased in 0.01 ng (28.1%) and
0.1 ng (29.6%) BMP-6 concentrations (P < 0.05) when
compared with 16.0% in the aged control mice, 11.6% in
1 ng BMP-6 and 3.2% in 10 ng BMP-6. This increased
embryo development rates in 0.01 ng and 0.1 ng BMP-6
were similar to that (35.8%) of the young control mice
(Table 1).
To investigate whether BMP-6 treatment during
superovulation influences ovarian expressions of Id-1
and VEGF, their expressions were examined by RT-PCR
and western blot in both ovaries of each mouse just after
zygotes collection. Both mRNA and protein expressions of
Id-1 and VEGF were significantly stimulated by 0.1 ng












0 (control) 7 118 1
26-31 (aged
control)
0 (control) 7 93 1
0.01 8 105 1
0.1 11 171 9
1 10 134 1
10 7 93 3
aP< .01 (vs. aged control, 0.01 ng, and 10 ng), bP< .05 (vs. aged control, 0.01 ng, anstimulated expression levels were comparable to those of
young positive control mice (Figure 1).
Immunohistochemistry was performed to evaluate the
localized Id-1 and VEGF expression in only 0.1 ng
BMP-6-treated ovaries because this dose of BMP-6
resulted in a significantly effect of BMP-6 on ovarian
response, oocyte quality, and the expression of Id-1 and
VEGF. The expressions of Id-1 and VEGF were localized
in oocytes, granulosa cells and stromal cells. The
immunoreactivity of Id-1 and VEGF revealed more
intense staining compared with aged control mice, but
similar intense staining to that of young control (Figure 2).
Discussion
The present study shows that co-administration of BMP-6
during superovulation in aged female mice improves the
number and developmental competence of oocytes ovu-
lated in an appropriate concentration. To our knowledge,
this is the first demonstration of the direct effect of BMP-6
on ovarian response, oocyte quality and ovarian expression
of angiogenic-related factors of aged female using a mouse
model.
The mechanisms for positive effects of BMP-6 on
ovarian response and oocyte quality of aged mice are as
yet unknown. However, one can consider two aspects;
the first is the effect of BMP-6 itself and the second is
the indirect effect of BMP-6 via the activation of ovarian
angiogenesis.
BMP-6 was abundantly present in the granulosa cells of
healthy follicle, not but in atretic follicles, of mammalian
ovary [32-34] and it prevents apoptosis of cumulus cells by
oocytes in a paracrine manner [17]. These results suggest
that BMP-6 may be an important mediator to support
healthy follicle growth in follicular development and
ovarian function. This hypothesis has been supported by
strong evidence of two in vivo studies by Campbell et al.
[21] and Sugiura et al. [22]. Campbell et al. showed that
direct ovarian infusion of BMP-6 resulted in increase in
ovarian inhibin A and estradiol secretion [21]. Sugiura et al.
reported that BMP-6 deficiency in female mice resulted in









2 (10.2%) 15.1 ± 4.7b 106 38 (35.8%)c
2 (12.9%) 11.6 ± 4.6 81 13 (16.0%)
6 (15.2%) 11.1 ± 5.5 89 25 (28.1%)c
(5.3%)a 14.7 ± 2.9b 162 48 (29.6%)c
3 (9.7%) 12.1 ± 4.5 121 14 (11.6%)
0 (32.3%) 9 ± 5.6 63 2 (3.2%)
d 10 ng), cP< .05 (vs. aged control, 1 ng and 10 ng).
Figure 1 Effects of administration of BMP-6 on ovarian expressions of Id-1 and VEGF. Eighteen hours after hCG injection, both whole
ovaries of each mouse were collected, and the expressions of ovarian Id-1 and VEGF were examined by RT-PCR and western blot. (A) Representative
RT-PCR for mRNA expression of ovarian Id-1 and VEGF. Levels of mRNA for Id-1 and VEGF were normalized to the amount of GAPDH per sample.
(B) Representative western blot products of protein expression for ovarian Id-1 and VEGF. Levels of protein for Id-1 and VEGF were normalized to the
amount of actin per sample. Data are representative of at least three independent experiments. The relative density of each gene was quantified with
NIH-Image J program (version 1.35d) (*P < 0.05 and **P < 0.01).
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BMP-6, the administration of BMP-6 during superovulation
may enhance not only ovarian response but also oocyte
quality, subsequently resulting in increased embryo
developmental competency.
An interesting finding in the present study was that
BMP-6 treatment also stimulated the expression of Id-1
and VEGF in the ovary. This result is consistent with the
report by Hogg et al. who showed that Id-1 expression was
significantly increased following BMP-6 stimulation of
granulosa cells in vitro [25]. VEGF is a well known
representative angiogenic factor and it plays a critical
role in the cyclic growth of ovarian follicles and mediates
ovarian angiogenesis [3,35].
Id proteins affect endothelial cells proliferation,
migration, invasion, and differentiation and have an
essential role in angiogenesis [24,30]. Many studies
demonstrated that Id-1 stimulates angiogenesis through the
activation of VEGF [31,36]. BMP-6 results in an advance in
the time of the LH surge [21] and LH surge have some
direct effects on angiogenesis to induce a series of cellular
and biochemical processes that culminate in ovulation [6].
In this regard, it can be postulated that the beneficial effect
of BMP-6 on oocyte quality and ovarian response may be
resulted from the activation of ovarian angiogenesis via up-
regulation of ovarian Id-1 and VEGF expression. Our
previous studies have demonstrated that the activationof ovarian angiogenesis by administration of angiogenic-
stimulating factors during ovulation induction could
improve ovarian response and oocyte quality with increased
expression of ovarian VEGF in aged female mice [37-39].
However, we did not assess ovarian Id-1 and VEGF
expression according to the time period after BMP-6
injection during the follicular development. Thus, further
study is needed to elucidate when Id-1 and VEGF
expression starts and continues after BMP-6 treatment.
Little data is available to confirm physiological
concentrations of BMP-6 in the ovary or serum [40].
Furthermore, reports on BMP-6 levels in mice are very
limited. Therefore, it was very difficult for us to determine
an optimal treatment concentration of BMP-6. Brankin
et al. investigated the effect of BMP-6 on steroidogenesis
and cell proliferation of in vitro cultured porcine theca cells
by adding various doses (0, 3, 30, 100 ng/mL) of BMP-6 to
culture medium [41]. Estradiol production and cell
proliferation were increased in 30 ng/ml BMP-6
concentration compared to other concentrations. Shi et al.
treated human granulosa cells with 100 ng/mL BMP-6 for
24 hours and investigated on gene expression of FSH
receptor, inhibin/activin, and anti-Mullerian hormones [15].
Campbell et al. directly infused 2 μg of BMP-6 to auto-
transplanted ovary in sheep and examined ovarian
hormone secretion [21]. Considering the BMP concentra-
tions of these studies, we treated 100 ng BMP-6, but the
Figure 2 Immunohistochemical analysis of Id-1 and VEGF in ovaries. Whole ovaries were collected 18 hours after hCG injection.
(A-C), young control mice; (D-F), aged control mice; (G-I), 0.1 ng BMP-6-treated aged mice. Control was immunostained without primary
antibody (purple color) (A, D, G). Cell immunostained with Id-1 (B, E, H) and VEGF (C, F, I)-specific antibody showed a brown color. n =3,
six ovaries per aged group (x 100 magnifications).
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embryo development rate of retrieved zygotes. Therefore,
we serially diluted this dose by ten times and treated with
BMP-6 concentrations ranging from 0.01 ng to 10 ng. The
treatment of 0.1 ng BMP-6 significantly increased all
parameters of the number of zygotes retrieved, blastocyst
formation rate, and ovarian Id-1 and VEGF expressions
compared to the control and other concentrations, whereas
1 ng and 10 ng BMP-6 decreased the embryo development
rate. Especially, 10 ng BMP-6 greatly reduced the number
of zygotes retrieved. In this respect, it is thought that 0.1 ng
of BMP-6 may be the optimal concentration required to
improve ovarian response and oocyte quality during ovarian
hyperstimulation in aged mice. The reason for inhibitory
effects by high concentrations of BMP-6 (10 ng) on the
number of ovulated oocytes and blastoocyst formation is
not clear, but may be attributable to the increased apoptosis
of granulosa cells [42].
Conclusions
The present study showed that co-administration of
BMP-6 with gonadotropin during superovulation in
aged mice increased the ovarian response, developmental
competence of oocytes and ovarian Id-1 and VEGF
expression. This study provides a notable finding that
BMP-6 can stimulate oocyte quality in aged femalealthough this study is done for a mouse model. This result
suggests the possibility that this research may have
potential clinical implications in the treatment of age-
related decline of fertility of women. However, our data
are insufficient to apply in the human being. Therefore,
first of all to apply the result of the present study, further
studies are needed to investigate BMP-6 levels in human
follicular fluid, serum, and ovarian tissues according to
women’s age, the number and quality of oocytes retrieved
during in vitro fertilization and embryo transfer.
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